X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
VVD-130850 is an investigational oral small molecule inhibitor of STAT3 transcription factor. It is being evaluated in phase 1 clinical trials in combination with pembrolizumab for the treatment of advanced solid tumors & advanced hematologic tumors.
Lead Product(s): VVD-130850,Pembrolizumab
Therapeutic Area: Oncology Product Name: VVD-130850
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 06, 2024
Details:
VVD-130037 is the investigational oral Kelch-like ECH Associated Protein 1 (KEAP1) activator, which is investigated for the treatment of advanced solid tumors.
Lead Product(s): VVD-130037
Therapeutic Area: Oncology Product Name: VVD-130037
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bayer AG
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2023
Details:
Tavros leverages its functional and computational genomics technologies to uncover unique vulnerabilities within tumors to discover novel targets and biomarkers in areas of high unmet clinical need and identify novel clinical positioning strategies for existing molecules.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Recipient: Tavros Therapeutics
Deal Size: $448.0 million Upfront Cash: $17.5 million
Deal Type: Collaboration October 12, 2022
Details:
Following closing of the acquisition, Bayer will own full rights to Vividion’s proprietary discovery platform, which comprises three integrated, synergistic components: a novel chemoproteomic screening technology, an integrated data portal, and a proprietary chemistry library.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bayer AG
Deal Size: $2,000.0 million Upfront Cash: $1,500.0 million
Deal Type: Acquisition August 05, 2021
Details:
The payment follows Vividion’s completion of a preclinical data package for a program addressing a well-known, but difficult to drug target, for the potential treatment of oncology indications.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Undisclosed Upfront Cash: $135.0 million
Deal Type: Collaboration June 24, 2021
Details:
Vividion’s initial wave of wholly owned assets includes programs targeting the KEAP1-NRF2 axis, with antagonists for the treatment of NRF2 mutant and NRF2 addicted cancers, as well as agonists for the treatment of inflammatory diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Logos Capital
Deal Size: $135.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing February 24, 2021
Details:
First reported E3 ligase beyond Cereblon and VHL shown to support broad targeted protein degradation of multiple targets in vivo.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
